Emerging Immunotherapy Approaches and MET

Inhibitors in Advanced NSCLC

Saturday 7 September, 11:30–13:00

Registration and lunch: 11:00

Hilton Head (1978), Hall 8.0, Fira de Barcelona, Spain

CME accredited lunch satellite symposium at the IASLC 2019 World Conference on Lung Cancer

Dear Colleague,

I would like to invite you to the lunch satellite symposium entitled Spotlight on Emerging Immunotherapy Approaches and MET Inhibitors in Advanced NSCLC, which will be held on Saturday 7 September. Please do join me in Hall 8.0, meeting room Hilton Head (1978)!

In a series of interactive panel presentations, the faculty of leading experts in non-small-cell lung cancer (NSCLC) will guide you through the latest advances in the field. They will discuss the rationale and evidence for novel immunotherapy approaches and the role of emerging MET inhibitors in overcoming challenges in your daily clinical practice. Recent diagnostic advances for personalizing treatment strategies in patients with advanced NSCLC will also be addressed.

On behalf of the faculty, I look forward to welcoming you at our symposium and are confident that it will be both an interesting and engaging educational event. We encourage you to join us to build on your knowledge and expertise in emerging therapeutic options for advanced NSCLC.

With kind regards,

Everett Vokes, Chair

Programme

11:30–11:40 Welcome and introduction Everett Vokes, University of Chicago, USA

11:40–12:05 What is the current clinical status of novel immunotherapies in advanced NSCLC? Luis Paz-Ares, Hospital 12 de Octubre, Spain

12:05–12:30 What does the latest evidence reveal for emerging MET inhibitors? Ross Camidge, University of Colorado Cancer Center, USA

12:30–12:55 Are we optimally prepared to provide personalized treatment strategies? Martin Reck, LungenClinic Grosshansdorf, Germany

12:55–13:00 Summary and adjournment

Please use this QR code for registration, accreditation and more information: www.ologyeducation.org/spotlightnsclc

Places & lunch: on a first-come, first-served basis

Fee information: no fee for this activity

This programme has been made possible thanks to an educational grant received from Merck KGaA, Darmstadt, Germany. Ology Medical Education is responsible for the medical support and delivery of content.

This program was approved by the IASLC 2019 World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 2019 World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC and is not part of the official IASLC accredited program.

EDUCATIONAL PARTNER

Booth #206